FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056574266> ?p ?o ?g. }

• W2056574266 endingPage "239" @default.
• W2056574266 startingPage "234" @default.
• W2056574266 abstract "Background & Aims The progression of liver fibrosis in patients with chronic hepatitis C (CHC) is important to decide on the treatment of the virus. As liver biopsy and liver stiffness measurement for staging of fibrosis present limitations, circulating levels of miR-122 have been suggested as a novel biomarker to predict the extent of liver injury. We evaluated the potential of miR-122 as an indicator of fibrosis progression in CHC infection and performed, for the first time, a comprehensive analysis of hepatic and circulating miR-122 levels in patients with CHC. Methods Patients with well-documented CHC infection were selected from the database of HepNet, the German-Competence-Network on Viral Hepatitis. All patients underwent blood sampling and liver biopsy with grading of inflammation and staging of fibrosis. RNA was extracted from 84 liver biopsies and 164 serum samples of CHC patients. miR-122 levels in liver and serum samples were quantified by real-time PCR normalized to RNU6 or spiked-in RNA, respectively. Results Hepatic levels of miR-122 decreased significantly with the severity of fibrosis (p= 0.001). In addition, circulating miR-122 levels correlated negatively with increasing stages of fibrosis, although the inverse correlation was moderate due to a two-phase miR-122 pattern during fibrosis progression. Thus, circulating miR-122 levels decreased in patients with severe fibrosis (F3, F4), while at early stages with distinct fibrotic structures (F2) and high inflammatory activity, miR-122 serum levels were elevated. Conclusions We conclude that during progression of fibrosis less miR-122 is released into the blood stream due to the loss of liver cells and the decrease of hepatic miR-122 levels. Although the release of circulating miR-122 possibly mirrors acute liver injury, in chronic liver disease and fibrosis, the loss of liver cells and the decreased hepatocellular miR-122 expression render miR-122 an inappropriate marker, when exclusively used for interpretation of fibrosis progression. The progression of liver fibrosis in patients with chronic hepatitis C (CHC) is important to decide on the treatment of the virus. As liver biopsy and liver stiffness measurement for staging of fibrosis present limitations, circulating levels of miR-122 have been suggested as a novel biomarker to predict the extent of liver injury. We evaluated the potential of miR-122 as an indicator of fibrosis progression in CHC infection and performed, for the first time, a comprehensive analysis of hepatic and circulating miR-122 levels in patients with CHC. Patients with well-documented CHC infection were selected from the database of HepNet, the German-Competence-Network on Viral Hepatitis. All patients underwent blood sampling and liver biopsy with grading of inflammation and staging of fibrosis. RNA was extracted from 84 liver biopsies and 164 serum samples of CHC patients. miR-122 levels in liver and serum samples were quantified by real-time PCR normalized to RNU6 or spiked-in RNA, respectively. Hepatic levels of miR-122 decreased significantly with the severity of fibrosis (p= 0.001). In addition, circulating miR-122 levels correlated negatively with increasing stages of fibrosis, although the inverse correlation was moderate due to a two-phase miR-122 pattern during fibrosis progression. Thus, circulating miR-122 levels decreased in patients with severe fibrosis (F3, F4), while at early stages with distinct fibrotic structures (F2) and high inflammatory activity, miR-122 serum levels were elevated. We conclude that during progression of fibrosis less miR-122 is released into the blood stream due to the loss of liver cells and the decrease of hepatic miR-122 levels. Although the release of circulating miR-122 possibly mirrors acute liver injury, in chronic liver disease and fibrosis, the loss of liver cells and the decreased hepatocellular miR-122 expression render miR-122 an inappropriate marker, when exclusively used for interpretation of fibrosis progression." @default.
• W2056574266 created "2016-06-24" @default.
• W2056574266 creator A5003722014 @default.
• W2056574266 creator A5025623640 @default.
• W2056574266 creator A5029282864 @default.
• W2056574266 creator A5036710220 @default.
• W2056574266 creator A5044488926 @default.
• W2056574266 creator A5054617732 @default.
• W2056574266 creator A5058743300 @default.
• W2056574266 creator A5060543893 @default.
• W2056574266 creator A5065099084 @default.
• W2056574266 creator A5070582544 @default.
• W2056574266 creator A5082162455 @default.
• W2056574266 creator A5083996468 @default.
• W2056574266 date "2013-02-01" @default.
• W2056574266 modified "2023-09-26" @default.
• W2056574266 title "Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis" @default.
• W2056574266 cites W144423133 @default.
• W2056574266 cites W1487011154 @default.
• W2056574266 cites W1812781790 @default.
• W2056574266 cites W1965815433 @default.
• W2056574266 cites W1969562548 @default.
• W2056574266 cites W1976528204 @default.
• W2056574266 cites W1980033422 @default.
• W2056574266 cites W1981772845 @default.
• W2056574266 cites W1981900811 @default.
• W2056574266 cites W1988986320 @default.
• W2056574266 cites W1989277040 @default.
• W2056574266 cites W1989941644 @default.
• W2056574266 cites W1994269019 @default.
• W2056574266 cites W1996867673 @default.
• W2056574266 cites W1999990472 @default.
• W2056574266 cites W2006531594 @default.
• W2056574266 cites W2007371170 @default.
• W2056574266 cites W2016340416 @default.
• W2056574266 cites W2026051181 @default.
• W2056574266 cites W2027498662 @default.
• W2056574266 cites W2029426792 @default.
• W2056574266 cites W2029807548 @default.
• W2056574266 cites W2032923154 @default.
• W2056574266 cites W2048091871 @default.
• W2056574266 cites W2049047145 @default.
• W2056574266 cites W2051678809 @default.
• W2056574266 cites W2058574629 @default.
• W2056574266 cites W2072442043 @default.
• W2056574266 cites W2072904045 @default.
• W2056574266 cites W2081814295 @default.
• W2056574266 cites W2087389370 @default.
• W2056574266 cites W2092170352 @default.
• W2056574266 cites W2092607950 @default.
• W2056574266 cites W2111848990 @default.
• W2056574266 cites W2114202720 @default.
• W2056574266 cites W2114658861 @default.
• W2056574266 cites W2115093090 @default.
• W2056574266 cites W2124358392 @default.
• W2056574266 cites W2128340149 @default.
• W2056574266 cites W2128366104 @default.
• W2056574266 cites W2128998001 @default.
• W2056574266 cites W2139342290 @default.
• W2056574266 cites W2146519879 @default.
• W2056574266 cites W2159954692 @default.
• W2056574266 cites W2161693225 @default.
• W2056574266 cites W2164724442 @default.
• W2056574266 cites W2164960736 @default.
• W2056574266 cites W2332313084 @default.
• W2056574266 cites W4211260107 @default.
• W2056574266 cites W4238801417 @default.
• W2056574266 cites W4241221175 @default.
• W2056574266 cites W4247258598 @default.
• W2056574266 cites W4255712601 @default.
• W2056574266 doi "https://doi.org/10.1016/j.jhep.2012.10.015" @default.
• W2056574266 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23085648" @default.
• W2056574266 hasPublicationYear "2013" @default.
• W2056574266 type Work @default.
• W2056574266 sameAs 2056574266 @default.
• W2056574266 citedByCount "149" @default.
• W2056574266 countsByYear W20565742662013 @default.
• W2056574266 countsByYear W20565742662014 @default.
• W2056574266 countsByYear W20565742662015 @default.
• W2056574266 countsByYear W20565742662016 @default.
• W2056574266 countsByYear W20565742662017 @default.
• W2056574266 countsByYear W20565742662018 @default.
• W2056574266 countsByYear W20565742662019 @default.
• W2056574266 countsByYear W20565742662020 @default.
• W2056574266 countsByYear W20565742662021 @default.
• W2056574266 countsByYear W20565742662022 @default.
• W2056574266 countsByYear W20565742662023 @default.
• W2056574266 crossrefType "journal-article" @default.
• W2056574266 hasAuthorship W2056574266A5003722014 @default.
• W2056574266 hasAuthorship W2056574266A5025623640 @default.
• W2056574266 hasAuthorship W2056574266A5029282864 @default.
• W2056574266 hasAuthorship W2056574266A5036710220 @default.
• W2056574266 hasAuthorship W2056574266A5044488926 @default.
• W2056574266 hasAuthorship W2056574266A5054617732 @default.
• W2056574266 hasAuthorship W2056574266A5058743300 @default.
• W2056574266 hasAuthorship W2056574266A5060543893 @default.
• W2056574266 hasAuthorship W2056574266A5065099084 @default.
• W2056574266 hasAuthorship W2056574266A5070582544 @default.

• next